{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:41:53Z","timestamp":1764906113828,"version":"3.44.0"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"European Alliance of Associations for Rheumatism"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,7,15]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is a lack of data on SARS-CoV-2 vaccination safety in children and young people (CYP) with rheumatic and musculoskeletal diseases (RMDs). Current vaccination guidance is based on data from adults with RMDs or CYP without RMDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the safety of SARS-COV-2 vaccination in adolescents with inflammatory RMDs and adults with juvenile idiopathic arthritis (JIA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We described patient characteristics, flares and adverse events (AEs) in adolescent cases under 18 with inflammatory RMDs and adult cases aged 18 or above with JIA submitted to the European Alliance of Associations for Rheumatology COVAX registry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 110 cases were reported to the registry. Thirty-six adolescent cases were reported from four countries, most with JIA (42%). Over half (56%) reported early reactogenic-like AEs. One mild polyarthralgia flare and one serious AE of special interest (malaise) were reported. No CYP reported SARS-CoV-2 infection postvaccination.<\/jats:p>\n                  <jats:p>Seventy-four adult JIA cases were reported from 11 countries. Almost two-thirds (62%) reported early reactogenic-like AEs and two flares were reported (mild polyarthralgia and moderate uveitis). No serious AEs of special interest were reported among adults with JIA. Three female patients aged 20\u201330\u2009years were diagnosed with SARS-CoV-2 postvaccination; all fully recovered.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This is an important contribution to research on SARS-CoV-2 vaccine safety in adolescents with RMDs and adults with JIA. It is important to note the low frequency of disease flares, serious AEs and SARS-CoV-2 reinfection seen in both populations, although the dataset is limited by its size.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002322","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T21:25:12Z","timestamp":1659302712000},"page":"e002322","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-162X","authenticated-orcid":false,"given":"Saskia","family":"Lawson-Tovey","sequence":"first","affiliation":[{"name":"Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK"},{"name":"National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK"},{"name":"National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany"}]},{"given":"Elsa","family":"Mateus","sequence":"additional","affiliation":[{"name":"Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal"},{"name":"Standing Committee of People with Arthritis\/Rheumatism in Europe (PARE), European League Against Rheumatism, Zurich, Switzerland"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, Sorbonne Universite, Paris, France"},{"name":"APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-2551","authenticated-orcid":false,"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[{"name":"Instituto de Salud Musculoesquel\u00e9tica, Madrid, Spain"}]},{"given":"Bernd","family":"Raffeiner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy"}]},{"given":"Inita","family":"Bulina","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Paul Stradins Clinical University Hospital, Riga, Latvia"},{"name":"Riga Stradins University, Riga, Latvia"}]},{"given":"Daniel","family":"Clemente","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Hospital Ni\u00f1o Jes\u00fas, Madrid, Spain"}]},{"given":"Julija","family":"Zepa","sequence":"additional","affiliation":[{"name":"Riga Stradins University, Riga, Latvia"},{"name":"Paul Stradins Clinical University Hospital, Riga, Latvia"}]},{"given":"Ana M.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisboa, Portugal"},{"name":"EpiDoC unit, CEDOC, Nova Medical School, Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Rheumatology, Universite Paris-Saclay, Assitance Publique-Hopitaux de Paris, INSERM UMR1184, Hopital Bicetre, Le Kremlin-Bicetre, France"}]},{"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[{"name":"National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK"}]}],"member":"239","published-online":{"date-parts":[[2022,7,31]]},"reference":[{"key":"2025090313421766000_8.2.e002322.1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090313421766000_8.2.e002322.2","unstructured":"PReS -- English . Guidelines and recommendations. Available: https:\/\/www.pres.eu\/clinical-affairs\/guidelines.html [Accessed 03 Dec 2021]."},{"key":"2025090313421766000_8.2.e002322.3","unstructured":"UK Health Security Agency . COVID-19: the green book, chapter 14A, 2022. Available: https:\/\/www.gov.uk\/government\/publications\/investigation-of- [Accessed 15 Jun 2022]."},{"key":"2025090313421766000_8.2.e002322.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220461"},{"key":"2025090313421766000_8.2.e002322.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1985"},{"key":"2025090313421766000_8.2.e002322.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647"},{"key":"2025090313421766000_8.2.e002322.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221217"},{"key":"2025090313421766000_8.2.e002322.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221607"},{"key":"2025090313421766000_8.2.e002322.9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/art.41977","article-title":"Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors","volume":"74","author":"Dimopoulou","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090313421766000_8.2.e002322.10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12969-021-00653-8","article-title":"Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication","volume":"19","author":"H\u00fcgle","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025090313421766000_8.2.e002322.11","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1093\/rheumatology\/keab169","article-title":"Survey of adult and paediatric rheumatology patients suggests information about COVID-19 vaccination will aid uptake","volume":"60","author":"Beesley","year":"2021","journal-title":"Rheumatology"},{"key":"2025090313421766000_8.2.e002322.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025090313421766000_8.2.e002322.13","unstructured":"Cdc COVID-19 study shows mRNA vaccines reduce risk of infection by 91 percent for fully vaccinated people | CDC online Newsroom | CDC. Available: https:\/\/www.cdc.gov\/media\/releases\/2021\/p0607-mrna-reduce-risks.html [Accessed 16 Aug 2021]."},{"key":"2025090313421766000_8.2.e002322.14","unstructured":"Comirnaty COVID-19 vaccine . Ema recommends approval for children aged 5 to 11 | European medicines Agency. Available: https:\/\/www.ema.europa.eu\/en\/news\/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11 [Accessed 13 Jan 2022]."},{"key":"2025090313421766000_8.2.e002322.15","unstructured":"GOV.UK . The MHRA concludes positive safety profile for Pfizer\/BioNTech vaccine in 12- to 15-year-olds. Available: https:\/\/www.gov.uk\/government\/news\/the-mhra-concludes-positive-safety-profile-for-pfizerbiontech-vaccine-in-12-to-15-year-olds [Accessed 03 Dec 2021]."},{"key":"2025090313421766000_8.2.e002322.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"2025090313421766000_8.2.e002322.17","unstructured":"COVID-19 vaccines advice. Available: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice [Accessed 16 Dec 2021]."},{"key":"2025090313421766000_8.2.e002322.18","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity following receipt of mRNA-based COVID-19 vaccines","volume":"325","author":"Chapin-Bardales","year":"2021","journal-title":"JAMA"},{"key":"2025090313421766000_8.2.e002322.19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2109522"},{"key":"2025090313421766000_8.2.e002322.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107456"},{"key":"2025090313421766000_8.2.e002322.21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116298"},{"key":"2025090313421766000_8.2.e002322.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.002"},{"key":"2025090313421766000_8.2.e002322.23","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00319-4"},{"key":"2025090313421766000_8.2.e002322.24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","article-title":"Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial","volume":"22","author":"Xia","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025090313421766000_8.2.e002322.25","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(22)00770-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"2025090313421766000_8.2.e002322.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221490"},{"key":"2025090313421766000_8.2.e002322.27","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac103","article-title":"Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications","author":"Heshin-Bekenstein","year":"2022","journal-title":"Rheumatology"},{"key":"2025090313421766000_8.2.e002322.28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1756-185X.14279","article-title":"Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: a single-center study","volume":"25","author":"Haslak","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"2025090313421766000_8.2.e002322.29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001814"},{"key":"2025090313421766000_8.2.e002322.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068665"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:42:28Z","timestamp":1756932148000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,31]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/rmdopen-2022-002322"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002322","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}